VA
VR Adviser Portfolio holdings
AUM
$1.33B
This Quarter Return
+6.49%
1 Year Return
+6.92%
3 Year Return
+862.77%
5 Year Return
+1,580.48%
10 Year Return
–
AUM
$779M
AUM Growth
+$779M
(-5.6%)
Cap. Flow
-$14.1M
Cap. Flow
% of AUM
-1.81%
Top 10 Holdings %
Top 10 Hldgs %
71.03%
Holding
35
New
6
Increased
2
Reduced
6
Closed
9
Top Buys
| 1 |
WHWK
Whitehawk Therapeutics, Inc. Common Stock
WHWK
|
$44.9M |
| 2 |
Travere Therapeutics
TVTX
|
$42M |
| 3 |
Nuvalent
NUVL
|
$18.1M |
| 4 |
Corvus Pharmaceuticals
CRVS
|
$16.6M |
| 5 |
ATYR
aTyr Pharma
ATYR
|
$14.2M |
Top Sells
| 1 |
PRVB
Provention Bio, Inc. Common Stock
PRVB
|
$24.5M |
| 2 |
Astria Therapeutics
ATXS
|
$23.8M |
| 3 |
TRIL
Trillium Therapeutics Inc.
TRIL
|
$19.4M |
| 4 |
ESSA Pharma
EPIX
|
$17.9M |
| 5 |
RAPT Therapeutics
RAPT
|
$12.4M |
Sector Composition
| 1 | Healthcare | 96.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Instil Bio
TIL
$182M
| $123M | 15.76% | 6,865,076 | – | – |
|
2
Aclaris Therapeutics
ACRS
$209M
| $82.2M | 10.55% | 4,563,962 | – | – |
|
3
Celldex Therapeutics
CLDX
$1.47B
| $59.3M | 7.62% | 1,098,174 -142,436 | -11% | -$7.69M |
|
|
WHWK
4
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$84.8M
| $44.9M | 5.77% | +1,529,402 | New | +$44.9M |
|
5
VistaGen Therapeutics
VTGN
$102M
| $44M | 5.65% | 16,047,286 | – | – |
|
6
Altimmune
ALT
$338M
| $43M | 5.52% | 3,800,000 +300,000 | +9% | +$3.39M |
|
7
Olema Pharmaceuticals
OLMA
$375M
| $42.3M | 5.44% | 1,536,193 | – | – |
|
|
8
Travere Therapeutics
TVTX
$1.56B
| $42M | 5.4% | +1,732,410 | New | +$42M |
|
9
Relmada Therapeutics
RLMD
$37.2M
| $36.4M | 4.67% | 1,387,720 | – | – |
|
10
GH Research
GHRS
$837M
| $36.2M | 4.65% | 1,642,296 +366,465 | +29% | +$8.08M |
|
|
KNTE
11
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $33.9M | 4.36% | 1,473,014 | – | – |
|
|
MRNS
12
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $30.1M | 3.86% | 2,641,809 | – | – |
|
|
LENZ
13
LENZ Therapeutics
LENZ
$1.1B
| $26.4M | 3.39% | 1,612,617 | – | – |
|
|
CNTA
14
Centessa Pharmaceuticals
CNTA
$2.25B
| $18.8M | 2.42% | 1,127,272 | – | – |
|
|
15
Nuvalent
NUVL
$5.52B
| $18.1M | 2.33% | +803,951 | New | +$18.1M |
|
|
16
Corvus Pharmaceuticals
CRVS
$428M
| $16.6M | 2.13% | +3,427,461 | New | +$16.6M |
|
17
Cullinan Oncology
CGEM
$445M
| $15.9M | 2.05% | 706,050 -270,095 | -28% | -$6.1M |
|
|
ATYR
18
aTyr Pharma
ATYR
$527M
| $14.2M | 1.83% | +1,565,000 | New | +$14.2M |
|
19
Athira Pharma
ATHA
$15.3M
| $11.2M | 1.44% | 1,196,196 -288,809 | -19% | -$2.71M |
|
20
Pharvaris
PHVS
$1.39B
| $9.8M | 1.26% | 552,882 -350,000 | -39% | -$6.21M |
|
21
Cogent Biosciences
COGT
$1.69B
| $9.16M | 1.18% | 1,088,817 | – | – |
|
22
CVRx
CVRX
$205M
| $8.82M | 1.13% | 533,370 -100,000 | -16% | -$1.65M |
|
|
AKYA
23
DELISTED
Akoya BioSciences
AKYA
| $5.58M | 0.72% | 400,000 | – | – |
|
|
24
Astria Therapeutics
ATXS
$349M
| $4.77M | 0.61% | 538,999 -2,695,001 | -83% | -$23.8M |
|
|
TCDA
25
DELISTED
Tricida, Inc. Common Stock
TCDA
| $1.81M | 0.23% | +390,707 | New | +$1.81M |
|